On February 25th, BofA analyst Matthew DeYoe resumed coverage and upgraded Celanese to Buy from Neutral with a price target of $140, up from $135. The company is coming off a tough Q4 print and softer outlook but there is reason to feel better about the outlook with acetyl prices in the U.S. faring much better than feared, the analyst tells investors in a research note. The firm adds that the risk-reward on the stock is turning "increasingly favorable".
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CE:
- Celanese and Alessa Therapeutics collaborate to advance oncology treatments
- Celanese price target lowered to $146 from $152 at BMO Capital
- Celanese announces Hytrel price increases
- Celanese price target lowered to $131 from $139 at RBC Capital
- Celanese price target raised to $113 from $107 at Mizuho
